JenaValve Technology
Dr Kenneth Macleod is a Partner at Rosetta Capital, a venture capital firm focussed on the life sciences and medical devices . Ken has over 35 years’ experience in the life sciences sector in a career combining senior operating roles in healthcare companies (Abbott Labs., Serono SA) and life science fund management (SV Health Investors, Paul Capital, Visium Healthcare Partners).
Ken currently holds board positions at Oxular Limited and has previously held board roles including at Pharming Group N.V. (NASDAQ:PHAR) and On-X Life Technologies, Inc., a mechanical heart valve company sold to Cryogenics Inc. (now NASDAQ:AORT).
Ken received a BSc in Biological Sciences from the University of Manchester and a D.Phil from the University of York.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
JenaValve Technology
1 followers
JenaValve Technology develops transcatheter aortic valve implantation (TAVI) systems for transapical and transfemoral implantation.